← ANALYST RATINGS · TIPRANKS
Contineum Therapeutics, Inc. Class A (CTNM): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy1 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $24.00, the highest $30.00, the lowest $17.00. The average is +239.0% from the last price of $7.08.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.50 → $7.00−17.6% | Hold | −1.1% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.00−12.5% | Hold | −1.1% | Upgrade | 17.10.26on TipRanks 08:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.50 → $7.00−17.6% | Hold | −1.1% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $7.00−12.5% | Hold | −1.1% | Reiterated | 17.10.26on TipRanks 08:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $6.50−18.8% | Sell | −8.2% | Downgrade | 17.10.26on TipRanks 08:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $6.50−18.8% | Sell | −8.2% | Downgrade | 17.10.26on TipRanks 08:06 | — | |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $24.00 → $30.00+25.0% | Buy | +323.7% | Reiterated | 14.10.26on TipRanks 07:30 | −2.2%next day −3.2% | ↗ |
| Charles Moore★★★★★★★★★★#5625 · hits 71% · avg +14.1% | Robert W. Baird | $19.00 → $14.00−26.3% | Hold | +97.7% | Downgrade | 13.10.26on TipRanks Oct 14 05:55 | −1.7%next day −2.2% | ↗ |
| Sean Laaman★★★★★★★★★★#446 · hits 67% · avg +17.2% | Morgan Stanley | $17.00 | Hold | +140.1% | Reiterated | 12.10.26on TipRanks 17:45 | −1.7%next day −2.2% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $29.00 → $28.00−3.4% | Buy | +295.5% | Reiterated | 12.10.26on TipRanks 10:25 | −35.9%next day −1.7% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 30.09.26on TipRanks 08:15 | +16.9%next day −3.4% · 5 days −7.1% | ↗ |
| Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% | LifeSci Capital | $23.00 | Buy | +224.9% | Reiterated | 29.09.26on TipRanks 16:25 | +16.9%next day −3.4% · 5 days −7.1% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $23.00 → $21.00−8.7% | Buy | +196.6% | Reiterated | 21.09.26on TipRanks 21:45 | −1.1%next day −5.9% · 5 days −13.0% | ↗ |
| Unknown Analyst | Leerink Partners | $25.00 → $22.00−12.0% | Buy | +210.7% | Reiterated | 16.09.26on TipRanks Sep 19 10:30 | 0.0%next day −5.1% · 5 days −11.2% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $22.00 → $21.00−4.5% | Buy | +196.6% | Reiterated | 15.12.25on TipRanks 09:40 | −0.3%next day 0.0% · 5 days +5.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Contineum Therapeutics, Inc. Class A
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.29 at a price of $13.42 (+66.1%); now: $22.14 at $7.08 (+212.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 4 | 5 | 2 | 10 | 11 |
| Buy | 3 | 2 | 4 | 2 | 6 | 4 |
| Hold | 2 | 1 | 1 | 1 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.45 (from $-0.51 to $-0.40). Last quarter: $-0.40.
Best top-analyst consensus in the sector · Healthcare
About Contineum Therapeutics, Inc. Class A
- CEO: Carmine N. Stengone
- Employees: 51
- 3565 General Atomics Court Suite 200, San Diego, CA, 92121, US
- www.contineum-tx.com
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Data from the stock’s TipRanks forecast page, read 61 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗